ASCI* in non-small cell lung cancer treatment
A new type of immunotherapy, called ASCI* (Antigen-Specific Cancer Immunotherapeutics), is being developed as a potential new non-small cell lung cancer treatment.
ASCI* works by educating our own natural immune system to fight cancer. It uses substances called a cancer antigen and an Adjuvant System to trigger and enhance an immune response against the cancer.
One of the antigens in lung cancer is called MAGE-A3. It is found in various cancers, including 30-40% of all non-small cell lung cancers (NSCLC).
Why ASCI* with MAGE-A3?
MAGE-A3 antigen is a good candidate for a potential new non-small cell lung cancer treatment because it is:
- A genuine cancer-specific antigen, present in 30-40% of patients with NSCLC
- Not found on the surface of normal cells
- Can be detected using appropriate laboratory tests
- Present in both early and advanced stages of the disease
MAGE-A3 ASCI* is still in clinical development and not yet approved for use outside of a clinical trial. Early studies have shown that it has potential for the treatment of NSCLC. This has prompted the launch of the MAGRIT clinical study. MAGRIT is a large international study that will assess the effectiveness of MAGE-A3 ASCI* in patients with NSCLC, and any side effects it may cause.
If you have been diagnosed with NSCLC and you are interested in taking part in the MAGRIT study, why not discuss it with your doctor? Use the link on the right of this page to find out more about the study and how to participate.
Next: Lung cancer clinical trials: find out more about the MAGRIT study
